- Home
- ADSE vs PRTA Comparison
ADSE vs PRTA Comparison
Compare ADSE & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADSE
- PRTA
- Stock Information
- Founded
- ADSE 1980
- PRTA 2012
- Country
- ADSE Ireland
- PRTA Ireland
- Employees
- ADSE N/A
- PRTA N/A
- Industry
- ADSE Industrial Specialties
- PRTA Biotechnology: Pharmaceutical Preparations
- Sector
- ADSE Consumer Discretionary
- PRTA Health Care
- Exchange
- ADSE Nasdaq
- PRTA Nasdaq
- Market Cap
- ADSE 705.5M
- PRTA 643.0M
- IPO Year
- ADSE N/A
- PRTA N/A
- Fundamental
- Price
- ADSE $15.61
- PRTA $13.77
- Analyst Decision
- ADSE Hold
- PRTA Buy
- Analyst Count
- ADSE 1
- PRTA 7
- Target Price
- ADSE $14.00
- PRTA $46.50
- AVG Volume (30 Days)
- ADSE 149.1K
- PRTA 711.1K
- Earning Date
- ADSE 09-12-2024
- PRTA 02-13-2025
- Dividend Yield
- ADSE N/A
- PRTA N/A
- EPS Growth
- ADSE N/A
- PRTA N/A
- EPS
- ADSE N/A
- PRTA N/A
- Revenue
- ADSE $158,974,606.00
- PRTA $133,350,000.00
- Revenue This Year
- ADSE $98.67
- PRTA $56.89
- Revenue Next Year
- ADSE $47.66
- PRTA N/A
- P/E Ratio
- ADSE N/A
- PRTA N/A
- Revenue Growth
- ADSE 168.42
- PRTA N/A
- 52 Week Low
- ADSE $6.36
- PRTA $11.70
- 52 Week High
- ADSE $16.22
- PRTA $34.75
- Technical
- Relative Strength Index (RSI)
- ADSE 67.38
- PRTA 48.19
- Support Level
- ADSE $14.70
- PRTA $12.39
- Resistance Level
- ADSE $15.40
- PRTA $13.64
- Average True Range (ATR)
- ADSE 0.79
- PRTA 1.03
- MACD
- ADSE -0.00
- PRTA -0.02
- Stochastic Oscillator
- ADSE 70.56
- PRTA 40.47
About ADSE ADS-TEC ENERGY PLC
ADS-TEC Energy PLC produces, develops, and markets battery-buffered EV charging systems infrastructure, battery storage systems, and cloud-based services which enable the customer to control and manage the system. Geographically, it derives a majority of its revenue from Europe.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).